Treatment-resistant depression (TRD) represents a substantial clinical and economic burden. A single subanesthetic dose of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine improves TRD depression symptoms within hours. 1 The rapid response points to a fundamentally different mechanism which, while well modeled in preclinical studies, has yet to be translated into clinically relevant biomarkers. Transcranial magnetic stimulation (TMS)-evoked potentials (TEPs) are a direct index of the neurophysiological state of the stimulated cortical and cortico-thalamic network. 2 TEPs have also previously shown a relationship with glutamatergic and Y-amino butyric acid (GABA)ergic neurotransmission suggesting that concurrent TMS-electroencephalography (EEG) can also be an index of local cortical excitability/inhibition balance. 2 Animal studies suggest that ketamine not only increases glutamatergic excitatory drive in the prefrontal cortex (PFC) and limbic regions of the brain 1 but also demonstrates GABA A R agonism. 3 This study aimed to observe changes in PFC cortical excitability measures indexed by a pharmaco-TMS-EEG approach by evaluating alterations in its component structure up to 24 hours postketamine infusion.
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Four TRD patients (mean age: 38.3 AE 10.6 years; N ¼ three females) provided written informed consent to participate. They received open-label intravenous infusion of 0.5 mg/kg ketamine over 40 minutes. Patient's depression levels were assessed using the Montgomery-Å sberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HAM-D) at pre-ketamine baseline, and 4 hours and 24 hours post-ketamine infusion. Concurrent TMS stimulation and EEG recording were performed at all sessions. Biphasic single-pulse TMS (MagVenture MagPro) was presented at the left dorsolateral prefrontal cortex (DLPFC), for N ¼ 200 pulses.
The cortical response to TMS was recorded using 64-channel EEG (BrainAmp DC, BrainProducts), sampled at 5000 Hz, with electrode wires reoriented to avoid direct contact with the TMS coil. Stimulation intensity was 120% of baseline resting motor threshold. EEG data were analyzed by replacing the TMS pulse period (0-20 ms) with linear interpolation. Artifacts were removed using a two-tiered independent components analysis routine (ARTIST). 4 This algorithm automatically identifies artifactual components based on features capturing the spatiotemporal profile of both neural and artifactual activities. Additional noise suppression employed the source-estimate-utilizing noisediscarding algorithm (SOUND). 5 We utilized the local mean field amplitude-area under the curve (LMFA-AUC) from a subset of electrodes ( Figure 1(d) ) around the stimulation site as our primary outcome measure. This has previously been reported as a reliable index of cortical reactivity or excitation. 6 We applied the SOUND correction to individual trials to test within-subject differences from session to session using nonparametric Kruskal-Wallis tests. Overall, patients showed a reduction in the LMFA-AUC at 4 hours that increased back at 24 hours but remained lower than baseline. We also found an overall reduction in peak-to-peak measures at N100, which is known to reflect cortical inhibition. 2, 7 The Kruskal-Wallis H test showed that there was a statistically significant difference in both N100 amplitude and LMFA-AUC between the sessions for all patients (p < 0.05). Follow-up pairwise comparisons of session with significance values adjusted by Bonferroni correction for multiple tests were conducted (Figure 2(c) and  (d) ). There was a reduction in the MADRS (42.2%) and HAM-D (47%) total depression scores between baseline and 24 hours for all patients except one (patient 4). There was a significant direct relationship between the depression scores (both HAM-D and MADRS) and LMFA-AUC values at 24 hours (p < 0.01) ( Figure 2) .
These preliminary results show the initial feasibility of the TMS-EEG approach to investigating DLPFC excitability and its relationship with antidepressant response in TRD. Previous studies have focused on motor-evoked potentials from TMS to the motor cortex, but very few have directly investigated TEPs from the DLPFC. Although ketamine has previously been reported to increase TMS-evoked motor cortical excitability, 8 we found reduced PFC excitability 4 hours after 0.5 mg/kg ketamine infusion (Figure 1(a) ). This can be interpreted as an alteration in excitatory/inhibitory balance. A recent TMS-EEG study of the DLPFC 9 demonstrated that the N100 amplitude and global mean field amplitude-area under the curve (GMFA-AUC) were higher in patients with major depressive disorder compared to healthy controls. This larger GMFA-AUC in the DLPFC corroborates with early EEG findings that show hyperactivation in endogenous depression patients, which normalizes after antidepressant treatment. 9, 10 Our study similarly provides a TMS-EEG paradigm for detecting the neuromodulatory effects of ketamine. Although the specific mechanisms by which excitation-inhibition balance is altered remains unclear, findings of GABA A R agonism decreasing N100 in motor cortex (while GABA B R agonism increases it) 7 suggest that effects may include modulation of GABA transmission. We acknowledge the preliminary nature of this small sample, but it could serve as a starting point for identifying clinical and EEG correlates of extended response in single-infusion ketamine studies and inform the design and interpretation of future multiple-infusion protocols. Furthermore, adequately powered studies will investigate whether altered PFC cortical excitability underlies depression and may be a biomarker of antidepressant treatment response in TRD.
